Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRAMADOL HYDROCHLORIDE vs ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: June 2026 · OpiCalc Medical Review Team
Tramadol hydrochloride is a centrally acting opioid analgesic that binds to μ-opioid receptors and inhibits the reuptake of norepinephrine and serotonin, modulating pain transmission in the central nervous system.
Acetaminophen: cyclooxygenase (COX) inhibitor, primarily central, analgesic and antipyretic. Aspirin: irreversible COX-1 and COX-2 inhibitor, analgesic, anti-inflammatory, antipyretic, antiplatelet. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.
Management of moderate to moderately severe pain (FDA-approved),Off-label: neuropathic pain, restless legs syndrome, osteoarthritis pain, fibromyalgia
Mild to moderate pain,Fever (acetaminophen and aspirin),Inflammatory conditions (aspirin)
50-100 mg orally every 4-6 hours as needed for pain, not to exceed 400 mg/day (100 mg for immediate-release).
1-2 tablets (each containing acetaminophen 300 mg, aspirin 300 mg, codeine phosphate 30 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets/day.
5-6 hours (parent drug); 7-9 hours (M1 active metabolite). In renal impairment, half-life prolonged up to 11 hours (parent) and 17 hours (M1).
Acetaminophen: 2-3 hours (terminal). Aspirin: 15-30 minutes (parent drug); salicylate: 2-3 hours at low doses, 15-30 hours at high doses due to saturable metabolism. Codeine: 2.5-4 hours. Clinical context: Prolonged half-life of salicylate at high doses increases risk of toxicity; hepatic impairment prolongs acetaminophen and codeine half-lives.
Extensively metabolized via O- and N-demethylation in the liver primarily by cytochrome P450 2D6 (CYP2D6) and CYP3A4, producing active metabolite O-desmethyltramadol (M1).
Acetaminophen: hepatic via CYP2E1, CYP1A2, CYP3A4; glucuronidation and sulfation; NAPQI formation. Aspirin: hepatic hydrolysis to salicylate; conjugation with glycine and glucuronic acid. Codeine: hepatic via CYP2D6 to morphine (active); also via CYP3A4 to norcodeine.
Primarily renal (90% total clearance, 30% as unchanged drug, 60% as metabolites); fecal (~10%); biliary minor.
Acetaminophen: renal excretion of metabolites (glucuronide and sulfate conjugates, ~85-90%), minor parent drug (<5%). Aspirin: renal excretion of salicylate and its metabolites (salicyluric acid, glucuronides, gentisic acid), dose-dependent; at therapeutic doses, ~50-80% as free salicylate and conjugates. Codeine: renal excretion of free and conjugated codeine (about 90%) and metabolites (morphine, norcodeine).
~20% bound to albumin. Low binding reduces drug interactions.
Acetaminophen: 10-25% (albumin). Aspirin: 50-80% (albumin), dose-dependent; salicylate: 75-90% (albumin). Codeine: ~7% (albumin).
2-3 L/kg (306 L total). Indicates extensive tissue distribution, including CNS penetration.
Acetaminophen: 0.9-1.0 L/kg (large distribution including liver). Aspirin: 0.15-0.2 L/kg (low Vd, confined to plasma and extracellular fluid); salicylate: 0.2-0.3 L/kg. Codeine: 3-6 L/kg (extensive tissue distribution). Clinical meaning: Large Vd for codeine suggests extensive tissue binding; aspirin Vd is small, consistent with limited extravascular distribution.
Oral: 70-75% (first-pass metabolism); IM: 100%; rectal: ~78% relative to oral; IV: 100%.
Oral: Acetaminophen: 85-95%. Aspirin: 40-60% (due to first-pass hydrolysis to salicylate). Codeine: ~50% due to first-pass metabolism.
For Cr Cl < 30 m L/min: increase dosing interval to 12 hours; maximum dose 200 mg/day. For Cr Cl < 10 m L/min: not recommended.
GFR 30-59 m L/min: Administer every 6 hours; maximum 6 tablets/day. GFR 15-29 m L/min: Administer every 12 hours; maximum 4 tablets/day. GFR <15 m L/min: Not recommended due to accumulation of codeine metabolites.
Child-Pugh Class B: reduce dose by 50% and extend interval to 12 hours. Child-Pugh Class C: not recommended.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50% and extend interval to every 6 hours; maximum 4 tablets/day. Child-Pugh Class C: Contraindicated.
1-2 mg/kg/dose every 4-6 hours, not to exceed 8 mg/kg/day or 400 mg/day (whichever less). Not recommended for children < 12 years for post-operative pain.
Not recommended for children <12 years due to aspirin risk of Reye syndrome. For children ≥12 years: Dose based on codeine component (0.5-1 mg/kg/dose) with maximum acetaminophen 75 mg/kg/day and aspirin 100 mg/kg/day. Typical: 1 tablet (acetaminophen 300 mg/aspirin 300 mg/codeine 30 mg) every 4-6 hours as needed; max 4 tablets/day.
Elderly (>75 years): use lowest effective dose, maximum 300 mg/day; extend dosing interval to 6-8 hours due to decreased clearance.
Start with lowest effective dose (e.g., 1 tablet every 6 hours); monitor renal and hepatic function; maximum 6 tablets/day due to increased sensitivity and risk of adverse effects.
WARNING: RISK OF MEDICATION ERRORS; ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P450 2D6 INTERACTION; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; SEROTONIN SYNDROME; HEPATIC TOXICITY
Risk of medication errors: confusion between different strengths and concentrations of acetaminophen can result in accidental overdose and fatal hepatotoxicity. Aspirin use in children and teenagers with viral infections is associated with Reye's syndrome.
Risk of serotonin syndrome when used with serotonergic drugs; risk of seizures in patients with epilepsy or those taking medications that lower seizure threshold; anaphylactic reactions; opioid-induced hyperalgesia; adrenal insufficiency; complex regional pain syndrome; withdrawal symptoms upon discontinuation.
Hepatotoxicity (acetaminophen dose >4 g/day), Reye's syndrome (aspirin in children), respiratory depression (codeine), tolerance/dependence, bleeding risk (aspirin), GI toxicity, renal impairment, hypersensitivity reactions.
Hypersensitivity to tramadol; acute or severe bronchial asthma; significant respiratory depression; gastrointestinal obstruction (including paralytic ileus); concurrent use of MAOIs or within 14 days of MAOI discontinuation; ethanol intoxication; severe hepatic impairment; use in children <12 years for postoperative tonsillectomy/adenoidectomy; known CYP2D6 ultra-rapid metabolizers.
Hypersensitivity to any component, active peptic ulcer disease, bleeding disorders, severe hepatic impairment, severe respiratory depression, children with viral illness (aspirin), pregnancy (third trimester for aspirin, codeine cautious).
Avoid alcohol consumption; may enhance CNS depression and increase risk of hepatotoxicity. Grapefruit juice may inhibit CYP2D6 and alter tramadol metabolism; limit intake. High-fat meals may delay absorption of immediate-release formulations but not significantly affect overall exposure.
Avoid alcohol due to increased risk of acetaminophen hepatotoxicity and aspirin-induced GI bleeding. Avoid large amounts of caffeine or high-tyramine foods (e.g., aged cheeses, cured meats) as they may affect CYP2D6 metabolism of codeine.
Tramadol hydrochloride is FDA Pregnancy Category C. First trimester: Limited human data; animal studies show increased skeletal variations and delayed ossification at maternally toxic doses. Second and third trimesters: Risk of neonatal respiratory depression, serotonin syndrome, and withdrawal if used near term. Avoid prolonged use or high doses.
Acetaminophen: Generally considered low risk; association with ASD and ADHD with prolonged use not fully established. Aspirin: First trimester: possible increased risk of gastroschisis; second trimester: relatively safe; third trimester: risk of premature closure of ductus arteriosus, oligohydramnios, and increased peripartum hemorrhage. Codeine: First trimester: possible neural tube defects; second and third trimesters: risk of respiratory depression, withdrawal in neonate with chronic use; neonatal opioid withdrawal syndrome (NOWS) possible.
Tramadol and its active metabolite O-desmethyltramadol (M1) are excreted into breast milk. Milk-to-plasma ratio is approximately 2.2 for tramadol and 2.9 for M1. Relative infant dose is estimated at 2.88% of maternal weight-adjusted dose. Although generally considered compatible, monitor infant for sedation, respiratory depression, and withdrawal symptoms. Use lowest effective dose for shortest duration.
Acetaminophen: M/P ratio approximately 0.91-1.42; considered safe. Aspirin: M/P ratio 0.08-0.15; high doses may cause Reye's syndrome; avoid or use low doses. Codeine: M/P ratio about 2.5; variable metabolism; risk of CNS depression in infant; avoid due to potential for toxicity in CYP2D6 ultrarapid metabolizers.
Pregnancy increases tramadol clearance due to enhanced hepatic metabolism and glomerular filtration. Dose adjustments are not standardized; however, increased doses may be needed to maintain analgesic efficacy. Use lowest effective dose and avoid during third trimester to prevent neonatal withdrawal and respiratory depression. Consider alternative analgesics if prolonged use required.
Acetaminophen: No dose adjustment needed. Aspirin: Avoid in third trimester; use lowest effective dose if necessary. Codeine: Avoid in pregnancy; if used, lowest effective dose for shortest duration; caution for CYP2D6 polymorphism. Pharmacokinetic changes: Increased clearance of codeine during pregnancy may require higher doses but risk outweighs benefit.
Tramadol is a prodrug requiring CYP2D6 metabolism to its active M1 metabolite for opioid analgesia; efficacy varies with CYP2D6 phenotype. Avoid concurrent use with MAOIs due to serotonin syndrome risk; use cautiously with SSRIs/SNRIs as additive serotonergic effects may occur. Tramadol lowers seizure threshold; avoid in patients with epilepsy or those taking other seizure threshold-lowering drugs. Renal impairment (Cr Cl < 30 m L/min) requires extended dosing interval (q12h). Do not exceed 400 mg/day (300 mg in elderly >75 years). Onset of analgesia is ~1 hour; peak effect at 2-3 hours.
Combination analgesic with acetaminophen (hepatotoxic at high doses), aspirin (antiplatelet, GI irritant, contraindicated in children <12 due to Reye's syndrome), and codeine (prodrug to morphine via CYP2D6; efficacy depends on CYP2D6 phenotype; risk of CNS/respiratory depression). Avoid in severe hepatic/renal impairment, active peptic ulcer, bleeding disorders, or concomitant use of other CNS depressants. Maximum acetaminophen dose from all sources: 4 g/day.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,May cause dizziness or drowsiness; avoid driving or operating machinery until you know how this medication affects you.,Risk of serotonin syndrome if combined with other serotonergic drugs (e.g., antidepressants, migraine medications); seek immediate medical attention if symptoms like agitation, hallucinations, rapid heart rate, or fever occur.,Do not crush, chew, or dissolve extended-release tablets; swallow whole.,Avoid alcohol and sedatives (e.g., benzodiazepines) as they increase risk of respiratory depression and oversedation.,Do not stop abruptly; withdrawal symptoms may occur. Taper under medical supervision.,Store at room temperature, away from moisture and heat, and out of reach of children.,Report any history of seizures, head injury, or substance abuse to your doctor.
Do not exceed recommended dose; acetaminophen overdosage can cause serious liver damage.,Do not take with other products containing acetaminophen or aspirin.,Avoid alcohol while taking this medication to reduce risk of liver toxicity and GI bleeding.,This product contains aspirin; do not give to children/teenagers with chickenpox or flu-like symptoms to avoid Reye's syndrome.,May cause drowsiness; do not drive or operate machinery until you know how you react.,Codeine is a narcotic pain reliever with abuse potential; use exactly as prescribed.,Seek medical attention if you experience signs of allergic reaction (rash, difficulty breathing) or bleeding (black/tarry stools, unusual bruising).
"Concomitant use of tramadol and secobarbital increases the risk of severe adverse effects, including profound sedation, respiratory depression, coma, and death. This is due to additive central nervous system depression from both drugs. Patients should be closely monitored for signs of respiratory depression and excessive sedation."
"Coadministration of tramadol, a weak mu-opioid receptor agonist and serotonin-norepinephrine reuptake inhibitor (SNRI), with pargyline, a nonselective monoamine oxidase inhibitor (MAOI), poses a significant risk of serotonin syndrome. This potentially life-threatening condition results from excessive serotonergic activity in the central nervous system, manifesting as altered mental status, autonomic instability, and neuromuscular hyperactivity. Additionally, tramadol's metabolism via CYP2D6 to its active metabolite M1, and use with an MAOI may lead to hypertensive crisis due to enhanced noradrenergic effects."
"Lisuride, a dopamine agonist, and tramadol, an opioid analgesic with serotonergic activity, synergistically increase the risk of serotonin syndrome, a potentially life-threatening condition characterized by altered mental status, autonomic instability, and neuromuscular hyperactivity. The combination may also potentiate CNS depression, leading to excessive sedation, respiratory depression, and impaired psychomotor function. Concurrent use should be avoided or undertaken with extreme caution due to the heightened risk of serious adverse outcomes."
"Pirenzepine, a selective M1 muscarinic antagonist, reduces gastrointestinal motility and secretions, while codeine, an opioid agonist, also decreases gastrointestinal motility via mu-opioid receptors. Concurrent use leads to additive anticholinergic and opioid effects, resulting in enhanced risk of severe constipation, paralytic ileus, and central nervous system depression. Clinically, patients may experience exacerbated sedation, respiratory depression, and urinary retention."
"Ropinirole, a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome, may reduce the analgesic efficacy of codeine. This is likely due to pharmacodynamic antagonism at central dopamine and opioid receptors, as well as potential pharmacokinetic interactions that decrease the conversion of codeine to its active metabolite morphine via CYP2D6 inhibition by ropinirole. The resultant blunted opioid response can lead to inadequate pain control, necessitating dose adjustment or alternative therapy."
"Vemurafenib induces CYP3A4, significantly reducing the plasma concentrations of codeine, which is metabolized via CYP3A4 to its active metabolite morphine. This may diminish codeine's analgesic efficacy, potentially leading to inadequate pain control. Additionally, reduced formation of morphine may lower the risk of opioid-related adverse effects."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRAMADOL HYDROCHLORIDE vs ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE, answered by our medical review team.
TRAMADOL HYDROCHLORIDE is a Opioid Agonist that works by Tramadol hydrochloride is a centrally acting opioid analgesic that binds to μ-opioid receptors and inhibits the reuptake of norepinephrine and serotonin, modulating pain transmission in the central nervous system.. ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE is a Opioid Agonist that works by Acetaminophen: cyclooxygenase (COX) inhibitor, primarily central, analgesic and antipyretic. Aspirin: irreversible COX-1 and COX-2 inhibitor, analgesic, anti-inflammatory, antipyretic, antiplatelet. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRAMADOL HYDROCHLORIDE and ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE depend on the specific clinical indication. These are both Opioid Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRAMADOL HYDROCHLORIDE is: 50-100 mg orally every 4-6 hours as needed for pain, not to exceed 400 mg/day (100 mg for immediate-release).. The standard adult dose of ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE is: 1-2 tablets (each containing acetaminophen 300 mg, aspirin 300 mg, codeine phosphate 30 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRAMADOL HYDROCHLORIDE and ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRAMADOL HYDROCHLORIDE is classified as Category D/X. Tramadol hydrochloride is FDA Pregnancy Category C. First trimester: Limited human data; animal studies show increased skeletal variations and delayed ossification at maternally to. ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE is classified as Category D/X. Acetaminophen: Generally considered low risk; association with ASD and ADHD with prolonged use not fully established. Aspirin: First trimester: possible increased risk of gastrosch. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.